Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
10.1042/BCJ20170920 4 AshouriS.KeyvanshokoohS.SalatiA
The LEADER trial with liraglutide and the REWIND trial with dulaglutide did not show significant increases in retinopathy complications, though differences in trial design, patient populations, baseline retinopathy prevalence, and rates of glycemic improvement may explain these discrepant findings
This was despite the fact that the work behind the patent, filed in 1997 and granted in 2001, demonstrated that the peptide helped to lower body weight for four weeks in type 2 diabetes patients who were obese (DiMarchi, Efendic)
Boehringer Ingelheim
Nonetheless, it had no impact on the body's natural glucose production, suggesting that the activation of MC3R and MC4R receptors in the central nervous system affects insulin sensitivity in a tissue-specific manner, independently [2]
US$ 29.51
US$ 21.88
US$ 23.54
US$ 28.01
